Group One Trading
CCCC icon

Group One Trading’s C4 Therapeutics CCCC Stock Holding History

Group One Trading’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$263 Sell
100
-3,000
-97% -$7.06K ﹤0.01% 7379
2025
Q4 		$5.92K Sell
3,100
-54,000
-95% -$128K ﹤0.01% 7105
2025
Q3 		$127K Buy
57,100
+47,100
+471% +$113K ﹤0.01% 5125
2025
Q2 		$14.3K Buy
10,000
+9,900
+9,900% +$14.4K ﹤0.01% 6493
2025
Q1 		$160 Sell
100
-600
-86% -$1.79K ﹤0.01% 7385
2024
Q4 		$2.52K Sell
700
-54,500
-99% -$271K ﹤0.01% 6665
2024
Q3 		$315K Buy
55,200
+30,900
+127% +$186K ﹤0.01% 3223
2024
Q2 		$112K Sell
24,300
-34,100
-58% -$203K ﹤0.01% 3875
2024
Q1 		$477K Sell
58,400
-120,800
-67% -$936K ﹤0.01% 2784
2023
Q4 		$1.01M Buy
+179,200
New +$409K ﹤0.01% 2454
2023
Q3 		– Sell
-100
Closed -$275 – 7680
2023
Q2 		$275 Buy
+100
New +$321 ﹤0.01% 7439

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Group One Trading's CCCC Position: Q1 2026 in Review

Group One Trading sold out of C4 Therapeutics (CCCC) in Q1 2026, closing a stake of 38,994 shares — an estimated $91.8K sold.

Group One Trading first reported a position in CCCC in Q3 2021 and held it in 8 quarters. The position peaked at $118K in Q4 2024. 123 funds tracked by Wall St. Rank hold CCCC as of Q1 2026.

  • Group One Trading reported no remaining C4 Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Group One Trading sold 38,994 C4 Therapeutics shares in Q1 2026, an estimated $91.8K.
  • Group One Trading first reported a position in C4 Therapeutics in Q3 2021 and held it in 8 quarters.
  • Group One Trading's C4 Therapeutics position peaked at $118K in Q4 2024.
  • 123 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.